Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Corbus Pharmaceuticals ( (CRBP) ) is now available.
On January 12, 2026, Corbus Pharmaceuticals updated its corporate presentation to highlight a diversified pipeline and key clinical milestones expected in 2026, underpinned by $173 million in cash, cash equivalents and investments as of November 3, 2025 and a relatively low share count of about 17.6 million common shares outstanding. The materials emphasize CRB-701 as a potentially best-in-class Nectin-4 antibody-drug conjugate with a proprietary design that delivers longer half-life, lower free MMAE exposure and a more convenient dosing regimen than current Nectin-4/MMAE competitors, alongside emerging safety data from a 167-patient dataset presented at ESMO 2025 showing lower rates of high-grade adverse events and peripheral neuropathy versus peer agents, positioning the drug to target high Nectin-4–expressing tumors such as head and neck, cervical and urothelial cancers. Corbus also outlines a 12-week, 240-patient mid-2026 obesity readout for CRB-913 and dose-escalation progress for CRB-601 in αvβ8-enriched solid tumors, signaling an active clinical year that could be pivotal for validating its oncology and metabolic franchises and strengthening its competitive standing in the ADC and obesity drug markets.
The most recent analyst rating on (CRBP) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Spark’s Take on CRBP Stock
According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.
The score is held down primarily by weak financial performance (no revenue, sizable losses, and material cash burn) and bearish technical trends (below major moving averages with negative MACD). Offsetting factors include favorable recent corporate milestones and financing that extends runway, but valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on CRBP stock, click here.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates and other targeted biologics for solid tumors and metabolic diseases. Its pipeline includes CRB-701, a Nectin-4 targeting ADC being developed in the U.S. and Europe for head and neck squamous cell carcinoma, cervical cancer and metastatic urothelial carcinoma; CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity and related conditions; and CRB-601, an anti-αvβ8 monoclonal antibody directed at TGFβ-targeting in solid tumors, with FDA Fast Track designation granted in head and neck and cervical cancer.
Average Trading Volume: 464,755
Technical Sentiment Signal: Sell
Current Market Cap: $146.7M
Find detailed analytics on CRBP stock on TipRanks’ Stock Analysis page.